A drug claimed to improve the condition of patients suffering from heart
failure is to get the backing of a PR campaign from joint marketers
SmithKline Beecham and Boehringer Mannheim UK.
The two pharmaceutical firms are poised to appoint a PR agency this week
to handle an educational campaign for Carvedilol, a beta blocker
normally prescribed for hypertension. Hill and Knowlton and Advisa
Medica have been shortlisted for the account, believed to be worth
pounds 60,000 in fees.
The winning agency will target cardiologists and GPs to explain the use
of Carvedilol, which has been tested in patient trials by SB and
Boehringer Mannheim since the 1980’s. Phase two of the campaign,
beginning next year, will target the public with the message that there
is a treatment available.